Abstract
Despite many improvements in thoracic surgery and oncology, the best treatment strategy for T4 non-small cell lung cancer(NSCLC) is yet to be identified. However, select patients without N2/N3 disease have been shown to be benefited from surgical resection. We aim to determine the impact of neoadjuvant chemotherapy and/or high-dose radiation therapy on survival in patients with T4N0-1 non-small cell lung cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
